Targeted Therapeutics for Transthyretin Cardiac Amyloidosis: Proof That Precision Medicine in Heart Failure Is a Possibility?

Sanjiv J. Shah

doi:10.1161/CIRCULATIONAHA.118.037593

Targeted Therapeutics for Transthyretin Cardiac Amyloidosis: Proof That Precision Medicine in Heart Failure Is a Possibility?

Sanjiv J. Shah^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	444-447
Number of pages	4
Journal	Circulation
Volume	139
Issue number	4
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.118.037593
State	Published - Jan 22 2019

Funding

Dr Shah is supported by grants from the National Institutes of Health (R01 HL140731, R01 HL120728, and R01 HL107577) and the American Heart Association (16SFRN28780016 and 15CVGPSD27260148) and by Actelion, Astra-Zeneca, Corvia, and Novartis; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics.

Keywords

Editorials
amyloidosis
heart failure
precision medicine

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1161/CIRCULATIONAHA.118.037593

Cite this

@article{7ec368d2875c4a4ab61446545d8d8864,

title = "Targeted Therapeutics for Transthyretin Cardiac Amyloidosis: Proof That Precision Medicine in Heart Failure Is a Possibility?",

keywords = "Editorials, amyloidosis, heart failure, precision medicine",

author = "Shah, {Sanjiv J.}",

note = "Funding Information: Dr Shah is supported by grants from the National Institutes of Health (R01 HL140731, R01 HL120728, and R01 HL107577) and the American Heart Association (16SFRN28780016 and 15CVGPSD27260148) and by Actelion, Astra-Zeneca, Corvia, and Novartis; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics.",

year = "2019",

month = jan,

day = "22",

doi = "10.1161/CIRCULATIONAHA.118.037593",

language = "English (US)",

volume = "139",

pages = "444--447",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Targeted Therapeutics for Transthyretin Cardiac Amyloidosis

T2 - Proof That Precision Medicine in Heart Failure Is a Possibility?

AU - Shah, Sanjiv J.

N1 - Funding Information: Dr Shah is supported by grants from the National Institutes of Health (R01 HL140731, R01 HL120728, and R01 HL107577) and the American Heart Association (16SFRN28780016 and 15CVGPSD27260148) and by Actelion, Astra-Zeneca, Corvia, and Novartis; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics.

PY - 2019/1/22

Y1 - 2019/1/22

KW - Editorials

KW - amyloidosis

KW - heart failure

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85060249556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060249556&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.118.037593

DO - 10.1161/CIRCULATIONAHA.118.037593

M3 - Review article

C2 - 30664380

AN - SCOPUS:85060249556

SN - 0009-7322

VL - 139

SP - 444

EP - 447

JO - Circulation

JF - Circulation

IS - 4

ER -

Targeted Therapeutics for Transthyretin Cardiac Amyloidosis: Proof That Precision Medicine in Heart Failure Is a Possibility?

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this